Ilia I. Ouspenski

Array ( [id] => 10506177 [patent_doc_number] => 09234043 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-01-12 [patent_title] => 'Anti-human OX40L antibodies' [patent_app_type] => utility [patent_app_number] => 14/811163 [patent_app_country] => US [patent_app_date] => 2015-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 67649 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14811163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729632 [patent_doc_number] => 20160075782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/807522 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44074 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714195 [patent_doc_number] => 20160060343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/805854 [patent_app_country] => US [patent_app_date] => 2015-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11575 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14805854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099229 [patent_doc_number] => 09856318 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS' [patent_app_type] => utility [patent_app_number] => 14/797894 [patent_app_country] => US [patent_app_date] => 2015-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21335 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14797894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10548524 [patent_doc_number] => 09273135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Human monoclonal antibodies to programmed death ligand 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 14/796956 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 65 [patent_no_of_words] => 44079 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 465 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12212142 [patent_doc_number] => 09908937 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-06 [patent_title] => 'Compositions monovalent for CD28 binding and methods of use' [patent_app_type] => utility [patent_app_number] => 14/740709 [patent_app_country] => US [patent_app_date] => 2015-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 62338 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14740709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106297 [patent_doc_number] => 09862767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Therapeutic methods using anti-CD200 antibodies' [patent_app_type] => utility [patent_app_number] => 14/739862 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 33503 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 446 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12945700 [patent_doc_number] => 09834606 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-05 [patent_title] => Anti-PD1 antibodies and their use as therapeutics and diagnostics [patent_app_type] => utility [patent_app_number] => 14/736966 [patent_app_country] => US [patent_app_date] => 2015-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 15943 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14736966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14609765 [patent_doc_number] => 10357561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-23 [patent_title] => BTNL9 proteins, nucleic acids, and antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 14/704794 [patent_app_country] => US [patent_app_date] => 2015-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 24264 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14704794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10103880 [patent_doc_number] => 09139653 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-09-22 [patent_title] => 'Anti-human OX40L antibodies and methods of treatment' [patent_app_type] => utility [patent_app_number] => 14/700896 [patent_app_country] => US [patent_app_date] => 2015-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 7 [patent_no_of_words] => 69575 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14700896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12086842 [patent_doc_number] => 09840562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-12 [patent_title] => 'Binding molecules to the human OX40 receptor' [patent_app_type] => utility [patent_app_number] => 14/692948 [patent_app_country] => US [patent_app_date] => 2015-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 16 [patent_no_of_words] => 23087 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14692948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10430268 [patent_doc_number] => 20150315281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/684550 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 26587 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14684550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333265 [patent_doc_number] => 20150218269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'USE OF TNFALPHA INHIBITOR FOR TREATMENT OF PSORIATIC ARTHRITIS' [patent_app_type] => utility [patent_app_number] => 14/681713 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22767 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333264 [patent_doc_number] => 20150218268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'Use of TNFalpha Inhibitor for Treatment of Psoriasis' [patent_app_type] => utility [patent_app_number] => 14/681704 [patent_app_country] => US [patent_app_date] => 2015-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23902 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14681704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693760 [patent_doc_number] => 20160039905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/679497 [patent_app_country] => US [patent_app_date] => 2015-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 61112 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14679497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693759 [patent_doc_number] => 20160039906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION' [patent_app_type] => utility [patent_app_number] => 14/679505 [patent_app_country] => US [patent_app_date] => 2015-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 35596 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14679505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936484 [patent_doc_number] => 20170240634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS' [patent_app_type] => utility [patent_app_number] => 15/125249 [patent_app_country] => US [patent_app_date] => 2015-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 24998 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15125249 [rel_patent_id] =>[rel_patent_doc_number] =>)